The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Imetelstat shows activity in patients with myeloproliferative neoplasms, including primary myelofibrosis (PMF) and essential thrombocythemia. Here, we describe a case of prolonged disease stabilization by imetelstat treatment of a high-risk PMF patient enrolled into the clinical study MYF2001. We co...

Full description

Bibliographic Details
Main Authors:	Kathrin Olschok, Bianca Altenburg, Marcelo A. S. de Toledo, Angela Maurer, Anne Abels, Fabian Beier, Deniz Gezer, Susanne Isfort, Katrin Paeschke, Tim H. Brümmendorf, Martin Zenke, Nicolas Chatain, Steffen Koschmieder
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-10-01
Series:	Frontiers in Oncology
Subjects:	Myeloproliferative neoplasms (MPN) imetelstat (GRN163L) myelofibrosis (MF) induced pluripotent stem cells telomere length (TL) JAK2V617F
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1277453/full

Similar Items

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
by: Kathrin Olschok, et al.
Published: (2023-08-01)

CRISPR/Cas9 mediated CXCL4 knockout in human iPS cells of polycythemia vera patient with JAK2 V617F mutation
by: Janik Boehnke, et al.
Published: (2021-08-01)

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
by: Lijuan Han, et al.
Published: (2016-05-01)

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN
by: Stefan Tillmann, et al.
Published: (2021-08-01)

Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms
by: Max Bermes, et al.
Published: (2023-12-01)

Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry
by: Vikas Bhuria, et al.
Published: (2024-03-01)

P1004: ACTIVATING MUTATIONS IN JAK2 AND CALR DIFFERENTIALLY AFFECT INTRACELLULAR CALCIUM LEVELS AND CALCIUM FLUX
by: Vikas Bhuria, et al.
Published: (2023-08-01)

Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita
by: Margherita Vieri, et al.
Published: (2020-09-01)

CRISPR/Cas9-engineered human ES cells harboring heterozygous and homozygous c-KIT knockout
by: Marcelo A.S. de Toledo, et al.
Published: (2022-04-01)

Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.
by: Martin M J Kirschner, et al.
Published: (2015-01-01)

Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors
by: Gabriela M. Baerlocher, et al.
Published: (2020-09-01)

Transient elastography in adult patients with cryptic dyskeratosis congenita reveals subclinical liver fibrosis: a retrospective analysis of the Aachen telomere biology disease registry
by: Mareike Tometten, et al.
Published: (2021-09-01)

Human DC3 Antigen Presenting Dendritic Cells From Induced Pluripotent Stem Cells
by: Taiki Satoh, et al.
Published: (2021-07-01)

Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm
by: Steffen Koschmieder, et al.
Published: (2018-06-01)

P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS
by: Kristin Holl, et al.
Published: (2023-08-01)

KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile
by: Marcelo A. S. de Toledo, et al.
Published: (2023-03-01)

Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells.
by: Richard K Lubberich, et al.
Published: (2018-01-01)

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
by: Kristin Holl, et al.
Published: (2024-02-01)

Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms
by: Nicolas Chatain, et al.
Published: (2020-08-01)

Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia
by: Margherita Vieri, et al.
Published: (2023-06-01)

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts
by: Sonali P. Barwe, et al.
Published: (2022-03-01)

Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
by: Margherita Vieri, et al.
Published: (2023-11-01)

Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
by: Benjamin Rolles, et al.
Published: (2021-08-01)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
by: Prithviraj Bose, et al.
Published: (2020-10-01)

P804: EX VIVO TREATMENT WITH ELTROMBOPAG RESCUES HEMATOPOIETIC STEM CELLS FROM ANTI-THYMOCYTE GLOBULIN-RELATED DAMAGE DURING IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH APLASTIC ANEMIA
by: M. Vieri, et al.
Published: (2022-06-01)

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
by: Oliver Herrmann, et al.
Published: (2019-07-01)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
by: Julian Baumeister, et al.
Published: (2021-12-01)

Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria
by: Mareike Tometten, et al.
Published: (2023-05-01)

Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation
by: Bennemann Karla, et al.
Published: (2012-08-01)

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
by: Henrike Jacobi, et al.
Published: (2023-07-01)

The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
by: Steffen Koschmieder
Published: (2021-06-01)

Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
by: Joao Gorgulho, et al.
Published: (2023-08-01)

PB1966: THE EFFECT OF BODY MASS INDEX ON THE SAFETY OF BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POST HOC POOLED DATA ANALYSIS
by: Susanne Isfort, et al.
Published: (2023-08-01)

DNA damage signaling in Drosophila macrophages modulates systemic cytokine levels in response to oxidative stress
by: Fabian Hersperger, et al.
Published: (2024-01-01)

P653: CML LONG-TERM LEUKEMIC STEM CELL PERSISTENCE IS INFLUENCED BY MYELOFIBROSIS AT DIAGNOSIS
by: Henrike Jacobi, et al.
Published: (2023-08-01)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
by: Saskia Maletzke, et al.
Published: (2022-01-01)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
by: Saskia Maletzke, et al.
Published: (2022-01-01)

Novel homozygous nonsense mutation in the P5′N‐1 coding gene as an alternative cause for hereditary anemia with basophilic stippling
by: Martin Kirschner, et al.
Published: (2022-03-01)

Is Treatment for Cytopenic Myelofibrosis Still an Unmet Clinical Need?
by: Madeline J. Caduc, et al.
Published: (2023-11-01)

Comprehensive characterization of chorionic villi-derived mesenchymal stromal cells from human placenta
by: Mónica S. Ventura Ferreira, et al.
Published: (2018-02-01)